Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Immuno-Oncology Drugs Elotuzumab Anti-LAG-3 and Anti-TIGIT

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents

pomalyst
immunomodulatory imide drug
pomalidomide
refractory multiple myeloma
monoclonal protein
  • 0 views
  • 28 Jul, 2021
  • 8 locations
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

patients with active multiple myeloma.

immunomodulatory imide drug
serum proteins
fludarabine
platelet count
cyclophosphamide
  • 47 views
  • 19 Feb, 2021
  • 7 locations
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

myeloma.To test the safety and efficacy of giving targeting CD138 or B-cell maturation antigen or CD19 or more antigens T cells in treating patients with multiple myeloma that is refractory to further

refractory multiple myeloma
leukemia
lymphoid leukemia
cell transplantation
cancer
  • 3 views
  • 22 Jan, 2021
  • 1 location
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR

refractory multiple myeloma
cancer
bcma
  • 6 views
  • 23 Jan, 2021
  • 1 location
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory Multiple Myeloma,however, a subset of patients relapse due to the loss of target in tumor cells.Dual

refractory multiple myeloma
bcma
  • 4 views
  • 22 Jan, 2021
  • 1 location
A Study to Investigate the Safety Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)

The purpose of this study is to determine the safety and tolerability of single agent TAK-573 in participants with relapsed/refractory MM in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-573 as a single agent and in combination with dexamethasone in participants with relapsed/refractory MM …

immunomodulatory imide drug
plasmacytosis
proteasome inhibitor
refractory multiple myeloma
measurable disease
  • 100 views
  • 28 Jan, 2021
  • 4 locations
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

patients with multiple myeloma. This is a dose escalation study of TMI with the primary objective of determining the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or

cell transplantation
cancer
refractory multiple myeloma
  • 9 views
  • 21 Jan, 2021
  • 1 location
A Phase I/IIa Clinical Trial to Assess Feasibility Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

Multiple myeloma (MM) is a rare hematologic malignancy of aberrant plasma cells. There is a high and currently unmet medical need for novel, innovative treatment concepts to improve the

immunomodulatory imide drug
cancer
chemotherapy regimen
lenalidomide
high dose chemotherapy
  • 67 views
  • 24 Jan, 2021
  • 1 location
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit.

immunoglobulin
immunomodulatory imide drug
hypercalcemia
recurrent disease
immunoglobulin a
  • 19 views
  • 25 Jun, 2021
  • 8 locations
A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma

TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies to treat participants who have relapsed or refractory multiple myeloma. The main aims of the study are to

  • 0 views
  • 11 Jul, 2021
  • 15 locations